Quidel recommences shipments of QuickVue+ lateral flow diagnostic test for infectious mononucleosis

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, announced today that it has begun taking orders for its QuickVue^®+ lateral flow diagnostic test for infectious mononucleosis. Due to strong customer demand, the Company has restarted manufacturing its previous mononucleosis product with shipments to customers expected during the first week of August.

"Our end users have expressed a strong desire for us to bring back our IgM-specific QuickVue+ Infectious Mononucleosis test. This test will strengthen our existing QuickVue respiratory franchise, while leveraging our QuickVue manufacturing efficiencies." said Douglas Bryant, president and chief executive officer of Quidel Corporation.

This 5-minute test continues to deliver IgM specificity in a unique plus/minus format with high clinical sensitivity and specificity.

Source Quidel Corporation